Statin treatment following coronary artery stenting and one-year survival.
暂无分享,去创建一个
A. Kastrati | J. Mehilli | J. Dirschinger | F. Neumann | M. Seyfarth | J. Pache | A. Schömig | H. Holle | K. Hösl | D. Kastrati
[1] Deepak L. Bhatt,et al. Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention , 2002, Circulation.
[2] S. Fichtlscherer,et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. , 2001, Journal of the American College of Cardiology.
[3] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[4] F Unger,et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.
[5] R. Califf,et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study , 2001, The Lancet.
[6] A. Zeiher,et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the Pl(A2)allele of the platelet glycoprotein IIIa gene. , 2001, European heart journal.
[7] D. Wood,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.
[8] L. Wallentin,et al. Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.
[9] D W Bates,et al. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. , 2001, Archives of internal medicine.
[10] U. Laufs,et al. Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription , 2000, Circulation.
[11] W. Palinski. Immunomodulation: a new role for statins? , 2000, Nature Medicine.
[12] A. Zeiher,et al. Effect of statin therapy on restenosis after coronary stent implantation. , 2000, The American journal of cardiology.
[13] M. Linton,et al. Current perspectives on statins. , 2000, Circulation.
[14] P. Rosenbaum,et al. Invited commentary: propensity scores. , 1999, American journal of epidemiology.
[15] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[16] T. Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.
[17] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[18] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[19] H. Krumholz,et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. , 1997, Circulation.
[20] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[21] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[22] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[23] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[24] W. O’Neill,et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.
[25] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[26] E J Topol,et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.
[27] P. Serruys,et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. , 1999, European heart journal.
[28] D Blumenthal,et al. Variations in cholesterol management practices of U.S. physicians. , 1997, Journal of the American College of Cardiology.
[29] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[30] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[31] N E Day,et al. Statistical methods in cancer research. IARC Workshop 25-27 May 1983. , 1987, IARC scientific publications.